These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 36662525)
1. Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System. Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Takhar H; Ogun OA; Simmons S; Zamparo JM; Tseng HF; Jodar L; McLaughlin JM JAMA Netw Open; 2023 Jan; 6(1):e2251833. PubMed ID: 36662525 [TBL] [Abstract][Full Text] [Related]
2. Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system. Bruxvoort KJ; Sy LS; Hong V; Lewin B; Qian L; Huang X; Holmquist KJ; Han B; Xu S Vaccine; 2023 Nov; 41(49):7460-7468. PubMed ID: 37953096 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840 [TBL] [Abstract][Full Text] [Related]
4. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals. Vo AD; La J; Wu JT; Strymish JM; Ronan M; Brophy M; Do NV; Branch-Elliman W; Fillmore NR; Monach PA JAMA Netw Open; 2022 Oct; 5(10):e2240037. PubMed ID: 36264571 [TBL] [Abstract][Full Text] [Related]
5. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. Smith JB; Gonzales EG; Li BH; Langer-Gould A JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148 [TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Not Completing a 2-Dose Primary Series of Messenger RNA COVID-19 Vaccination in a Large Health Care System in Southern California: Retrospective Cohort Study. Xu S; Hong V; Sy LS; Bruxvoort KJ; Lewin B; Han B; Holmquist KJ; Qian L JMIR Public Health Surveill; 2023 Oct; 9():e46318. PubMed ID: 37792452 [TBL] [Abstract][Full Text] [Related]
8. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
9. Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England. Chen DT; Copland E; Hirst JA; Mi E; Dixon S; Coupland C; Hippisley-Cox J BMC Med; 2024 Jun; 22(1):237. PubMed ID: 38858672 [TBL] [Abstract][Full Text] [Related]
10. Infections, Hospitalizations, and Deaths Among US Nursing Home Residents With vs Without a SARS-CoV-2 Vaccine Booster. McConeghy KW; Bardenheier B; Huang AW; White EM; Feifer RA; Blackman C; Santostefano CM; Lee Y; DeVone F; Halladay CW; Rudolph JL; Zullo AR; Mor V; Gravenstein S JAMA Netw Open; 2022 Dec; 5(12):e2245417. PubMed ID: 36477482 [TBL] [Abstract][Full Text] [Related]
11. Rates of and Factors Associated With Primary and Booster COVID-19 Vaccine Receipt by US Veterans, December 2020 to June 2022. Bajema KL; Rowneki M; Berry K; Bohnert A; Bowling CB; Boyko EJ; Iwashyna TJ; Maciejewski ML; O'Hare AM; Osborne TF; Viglianti EM; Hynes DM; Ioannou GN JAMA Netw Open; 2023 Feb; 6(2):e2254387. PubMed ID: 36729454 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months. Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331 [TBL] [Abstract][Full Text] [Related]
14. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999 [TBL] [Abstract][Full Text] [Related]
15. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661 [TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
17. Time to COVID-19 Vaccination by Language and Country of Origin. Nolan MB; Chrenka E; DeSilva MB JAMA Netw Open; 2024 Oct; 7(10):e2437388. PubMed ID: 39361282 [TBL] [Abstract][Full Text] [Related]
18. Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. Wu JT; La J; Branch-Elliman W; Huhmann LB; Han SS; Parmigiani G; Tuck DP; Brophy MT; Do NV; Lin AY; Munshi NC; Fillmore NR JAMA Oncol; 2022 Feb; 8(2):281-286. PubMed ID: 34854921 [TBL] [Abstract][Full Text] [Related]
19. Factors Associated With COVID-19 Vaccine Receipt by Health Care Personnel at a Major Academic Hospital During the First Months of Vaccine Availability. Green-McKenzie J; Shofer FS; Momplaisir F; Kuter BJ; Kruse G; Bialal U; Behta M; O'Donnell J; Al-Ramahi N; Kasbekar N; Sullivan P; Okala P; Brennan PJ JAMA Netw Open; 2021 Dec; 4(12):e2136582. PubMed ID: 34851399 [TBL] [Abstract][Full Text] [Related]
20. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021. Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]